OpenAI has met with representatives of the US Food and Drug Administration (FDA) to discuss the agency’s use of artificial intelligence to speed up drug evaluations, Wired reported on Wednesday.
According to the report, OpenAI and the FDA discussed a project called cderGPT, which appears to be an AI tool for the Center for Drug Evaluation (CDE). The CDE regulates over-the-counter and prescription drugs in the United States. Reportedly, partners from Elon Musk’s DOGE also participated in the negotiations.
Drug development processes often take more than ten years. OpenAI’s collaboration with the FDA aims to speed up a small part of this process, towards the end, Wired reports. AI has long been touted as a potential accelerator that can be used in the drug development process, making some of the notoriously slow steps more efficient. However, there are still unanswered questions about how to control the unreliability of AI models.
